• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Taurinated bile acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Bile acids, alcohols and derivatives Taurinated bile acids and derivatives

Recent Advances in Taurodeoxycholic Acid (516-50-7) Research: Implications for Chemical Biology and Medicine

Taurodeoxycholic acid (TUDCA, CAS: 516-50-7), a bile acid conjugate, has garnered significant attention in recent years due to its diverse biological activities and therapeutic potential. This research brief synthesizes the latest findings on TUDCA, focusing on its molecular mechanisms, applications in disease treatment, and emerging trends in pharmaceutical development. The compound's unique chemical properties, including its amphipathic nature and ability to modulate cellular signaling pathways, make it a promising candidate for addressing complex medical challenges.

A 2023 study published in Nature Chemical Biology elucidated the structural basis for TUDCA's chaperone-like activity, revealing how its specific interactions with misfolded proteins contribute to endoplasmic reticulum (ER) stress reduction. The research team employed cryo-EM and molecular dynamics simulations to demonstrate TUDCA's binding affinity for key ER stress sensors (PERK, IRE1α, and ATF6), providing atomic-level insights into its mechanism of action. These findings have important implications for developing TUDCA-based therapies for protein misfolding diseases such as Alzheimer's and Parkinson's.

In the field of metabolic disorders, a recent clinical trial (NCT05243031) investigated TUDCA's efficacy in non-alcoholic fatty liver disease (NAFLD). The phase IIb study, reported in Hepatology (2024), showed that 1000 mg/day TUDCA administration for 24 weeks significantly improved liver enzyme levels, reduced hepatic fat content (measured by MRI-PDFF), and enhanced insulin sensitivity. Notably, the treatment group exhibited a 38% reduction in fibrosis markers compared to placebo, suggesting TUDCA's potential as a multi-target therapeutic for metabolic syndrome.

Pharmaceutical formulation research has made notable progress in overcoming TUDCA's bioavailability challenges. A 2024 patent (WO2024015832) describes novel liposomal encapsulation techniques that increase TUDCA's oral bioavailability by 3.2-fold while maintaining its biological activity. This advancement, coupled with improved synthetic methods for GMP-grade TUDCA production (Organic Process Research & Development, 2023), addresses previous limitations in clinical translation and commercial scalability.

Emerging applications in neuroprotection have expanded TUDCA's therapeutic scope. Preclinical studies in Amyotrophic Lateral Sclerosis (ALS) models (Cell Reports Medicine, 2024) demonstrate that TUDCA crosses the blood-brain barrier more efficiently than previously thought, accumulating in motor neurons at concentrations sufficient to inhibit apoptosis pathways. These findings support the ongoing phase III clinical evaluation of TUDCA in ALS (NCT05347849), with interim results expected in Q4 2024.

The chemical biology of TUDCA continues to reveal novel mechanisms. Recent work in Science Signaling (2024) identified TUDCA as an allosteric modulator of the TGR5 receptor, explaining its paradoxical effects on both inflammatory and metabolic pathways. This discovery opens new avenues for designing TUDCA derivatives with enhanced receptor specificity, potentially leading to next-generation therapeutics with fewer off-target effects.

Quality control and analytical methods for TUDCA have also advanced significantly. The 2024 revision of USP-NF standards includes new HPLC-ELSD protocols for TUDCA purity assessment, addressing previous challenges in quantifying minor bile acid impurities. These improvements in quality assurance support the growing pharmaceutical applications of TUDCA, particularly in injectable formulations where purity requirements are stringent.

Looking forward, the TUDCA research landscape appears poised for transformative developments. The compound's pleiotropic effects, combined with advances in targeted delivery systems and structure-activity relationship understanding, position it as a versatile scaffold for both monotherapies and combination treatments. Ongoing research into TUDCA's epigenetic modulatory effects and microbiome interactions suggests its therapeutic potential may extend beyond current applications, potentially impacting areas such as aging biology and immune modulation.

• 13164-16-4(Taurodeoxycholsaeure)
• 149404-84-2(Taurodeoxycholsaeure)
• 32747-06-1(Taurocholat)
• 14605-22-2(Tauroursodeoxycholate)
• 107656-89-3(Taurocholat)
• 90082-01-2(Taurocholat)
• 516-35-8(Taurochenodeoxycholic acid)
• 111187-84-9(Taurodeoxycholsaeure)
• 130009-01-7(Taurodeoxycholsaeure)
• 90082-04-5(Taurocholat)